# US 2024/0199732 A1 · Anti-IL-27 Antibodies and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199732 A1
- Document ID: US20240199732A1
- Status: Published application
- Kind: A1
- Application number: 18/307,850
- Filed: 2023-04-27
- Published: 2024-06-20
- Earliest claimed: 2019-09-25
- Assignees: Surface Oncology, Inc.
- Applicants: Surface Oncology, LLC
- Inventors: Jamie Strand; Jonathan Hill; Devan Moodley
- Web page: https://patentgrep.com/patent/US20240199732A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

## Claims

### Claim at position 1

1-80. (canceled)

### Claim 81

A method for producing an antibody, or an antigen binding portion thereof, comprising culturing a cell to express the antibody or antigen binding portion thereof, wherein the antibody or antigen binding portion thereof comprises:
(a) a heavy chain CDR1 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 9, 31, 53, 75, 97, or 119;
(b) a heavy chain CDR2 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 10, 32, 54, 76, 98, or 120;
(c) a heavy chain CDR3 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 11, 33, 55, 77, 99, or 121;
(d) a light chain CDR1 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 17, 39, 61, 83, 105, or 127;
(e) a light chain CDR2 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 18, 40, 62, 84, 106, or 128; and
(f) a light chain CDR3 comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 19, 41, 63, 85, 107, or 129.

### Claim 82 (depends on 81)

The method of claim 81, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1 an IgA2, an IgD, and an IgE antibody.

### Claim 83 (depends on 82)

The method of claim 82, wherein the antibody is an IgG1 antibody or an IgG4 antibody.

### Claim 84 (depends on 81)

The method of claim 81, wherein the antibody comprises an IgG1 heavy chain constant region or an IgG4 heavy chain constant region.

### Claim 85 (depends on 81)

The method of claim 81, wherein the antibody comprises an Fc domain comprising at least one mutation.

### Claim 86 (depends on 85)

The method of claim 85, wherein the antibody comprises an IgG4 heavy chain comprising a substitution selected from the group consisting of S228P, L235E, L235A, and any combination thereof, according to EU numbering.

### Claim 87 (depends on 81)

The method of claim 81, wherein the antibody or antigen binding portion thereof comprises a variable heavy chain comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 15, 37, 59, 81, 103, and 125.

### Claim 88 (depends on 81)

The method of claim 81, wherein the antibody or antigen binding portion thereof comprises a variable light chain comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 23, 45, 67, 89, 111, and 133.

### Claim 89 (depends on 81)

The method of claim 81, wherein the cell is a mammalian cell.

### Claim 90 (depends on 81)

The method of claim 81, wherein the cell is a yeast cell.

### Claim 91 (depends on 81)

The method of claim 81, further comprising purifying the antibody or antigen binding portion thereof.

### Claim 92 (depends on 91)

The method of claim 91, wherein the purifying comprises using a chromatographic technique selected from ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, reverse-phase HPLC chromatography, or a combination thereof.

### Claim 93 (depends on 91)

The method of claim 91, wherein the purifying comprises using an immunological technique.

### Claim 94 (depends on 91)

The method of claim 91, wherein the purifying comprises using a protein-A chromatography column.

### Claim 95 (depends on 81)

The method of claim 81, further comprising conjugating a therapeutic agent to the antibody or antigen binding portion thereof.

### Claim 96 (depends on 81)

The method of claim 81, wherein the antibody or antigen binding portion thereof is glycosylated.

### Claim 97 (depends on 81)

The method of claim 81, further comprising PEGylating the antibody or antigen binding portion thereof.

### Claim 98

A method for producing an antibody, or an antigen binding portion thereof, comprising culturing a cell to express the antibody or antigen binding portion thereof,
wherein the antibody or antigen binding portion thereof comprises heavy and light chain CDRs, wherein:
(a) the light chain CDR1 consists of N-XXXXXXLFSSNXKXYXX-C;
(b) the light chain CDR2 consists of the sequence set forth in SEQ ID NO: 131;
(c) the light chain CDR3 consists of N-XXXASAXXX-C;
(d) the heavy chain CDR1 consists of the sequence set forth in SEQ ID NO: 122;
(e) the heavy chain CDR2 consists of N-XXSSSXSYXYXXXXXXX-C; and
(f) the heavy chain CDR3 consists of N-XXXXGRTSYTATXHNXXXX-C;
wherein X is any amino acid.

### Claim 99 (depends on 98)

The method of claim 98, wherein the antibody is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1 an IgA2, an IgD, and an IgE antibody.

### Claim 100 (depends on 99)

The method of claim 99, wherein the antibody is an IgG1 antibody or an IgG4 antibody.

### Claim 101 (depends on 98)

The method of claim 98, wherein the antibody comprises an IgG1 heavy chain constant region or an IgG4 heavy chain constant region.

### Claim 102 (depends on 98)

The method of claim 98, wherein the antibody comprises an Fc domain comprising at least one mutation.

### Claim 103 (depends on 102)

The method of claim 102, wherein the antibody comprises an IgG4 heavy chain comprising a substitution selected from the group consisting of S228P, L235E, L235A, and any combination thereof, according to EU numbering.

### Claim 104 (depends on 98)

The method of claim 98, wherein the cell is a mammalian cell.

### Claim 105 (depends on 98)

The method of claim 98, wherein the cell is a yeast cell.

### Claim 106 (depends on 98)

The method of claim 98, further comprising purifying the antibody or antigen binding portion thereof.

### Claim 107 (depends on 106)

The method of claim 106, wherein the purifying comprises using a chromatographic technique selected from ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, reverse-phase HPLC chromatography, or a combination thereof.

### Claim 108 (depends on 106)

The method of claim 106, wherein the purifying comprises using an immunological technique.

### Claim 109 (depends on 106)

The method of claim 106, wherein the purifying comprises using a protein-A chromatography column.

### Claim 110 (depends on 98)

The method of claim 98, further comprising conjugating a therapeutic agent to the antibody or antigen binding portion thereof.

### Claim 111 (depends on 98)

The method of claim 98, wherein the antibody or antigen binding portion thereof is glycosylated.

### Claim 112 (depends on 98)

The method of claim 98, further comprising PEGylating the antibody or antigen binding portion thereof.
